Philip Morris has raised its bid for British drugmaker Vectura to 165 pence (US$2.29) per share, the tobacco company stated on Sunday, August 8.
“The PMI (Philip Morris International) increased offer values the entire issued and to be issued ordinary share capital of Vectura at approximately 1.02 billion pounds ($1.41 billion),” it wrote in an emailed statement to Reuters.
The latest offer represents a premium of approximately 10 pence per share to a rival offer of 155 pence a share by US-based Carlyle Group announced on Friday.
Carlyle offered to buy Vectura for about £958 million (US$1.3 billion). Vectura, which makes respiratory treatments, had stated on Friday that it was backing Carlyle’s offer and withdrawing its recommendation for Philip Morris’ proposal, adding that it might be better positioned under Carlyle’s ownership.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI